title: Use of sevelamer in chronic kidney disease: beyond phosphorus control.
abstract: Sevelamer is a non-calcium phosphate binder used in advanced chronic kidney disease (CKD) and in dialysis for hyperphosphataemia control. Several experimental, observational studies and clinical trials have shown that sevelamer has pleiotropic effects, beyond hyperphosphataemia control, including actions on inflammation, oxidative stress, lipid profile and atherogenesis, vascular calcification, endothelial dysfunction and the reduction of several uremic toxins. This is the biological basis for its global effect on cardiovascular morbidity and mortality in patients with chronic kidney disease. This review focuses on these pleiotropic actions of sevelamer and their impact on cardiovascular health, with the experience published after more than ten years of clinical expertise.
authors: Servicio de Nefrología. Fundación Jiménez Díaz. Madrid (España).
authors: Laura
authors: L
authors: Rodríguez-Osorio
authors: Servicio de Nefrología. Fundación Jiménez Díaz. Madrid (España).
authors: Diana Pazmiño
authors: DP
authors: Zambrano
authors: Servicio de Nefrología. Fundación Jiménez Díaz. Madrid (España).
authors: Carolina
authors: C
authors: Gracia-Iguacel
authors: Servicio de Nefrología. Fundación Jiménez Díaz. Madrid (España).
authors: Jorge
authors: J
authors: Rojas-Rivera
authors: Servicio de Nefrología. Fundación Jiménez Díaz. Universidad Autónoma de Madrid. Madrid (España).
authors: Alberto
authors: A
authors: Ortiz
authors: Servicio de Nefrología. Fundación Jiménez Díaz. Universidad Autónoma de Madrid. Madrid (España).
authors: Jesus
authors: J
authors: Egido
authors: Servicio de Nefrología. Fundación Jiménez Díaz. Universidad Autónoma de Madrid. Madrid (España). Electronic address: egparra@fjd.es.
authors: Emilio
authors: E
authors: González Parra
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects; D002114:Calcinosis / Q000188:drug therapy; D002614:Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000187:drug effects; D004731:Endotoxins / Q000493:pharmacokinetics; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D007249:Inflammation; D007408:Intestinal Absorption / Q000187:drug effects; D008903:Minerals / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D010758:Phosphorus / Q000378:metabolism*; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000378:metabolism; D000069603:Sevelamer / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D014511:Uremia / Q000188:drug therapy / Q000378:metabolism; D014652:Vascular Diseases / Q000188:drug therapy
chemical_list: D000924:Anticholesteremic Agents; D002614:Chelating Agents; D004731:Endotoxins; D017127:Glycation End Products, Advanced; D008903:Minerals; D010758:Phosphorus; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D000069603:Sevelamer
keywords: Efectos pleiotrópicos; Fósforo; Gut; Inflamación e intestino; Inflammation; Phosphate; Pleiotropic effects; Sevelamer